| __timestamp | Neurocrine Biosciences, Inc. | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 14097000000 |
| Thursday, January 1, 2015 | 32480000 | 14809000000 |
| Friday, January 1, 2016 | 68081000 | 14837000000 |
| Sunday, January 1, 2017 | 169906000 | 14784000000 |
| Monday, January 1, 2018 | 248932000 | 14455000000 |
| Tuesday, January 1, 2019 | 354100000 | 14350000000 |
| Wednesday, January 1, 2020 | 433300000 | 11615000000 |
| Friday, January 1, 2021 | 583300000 | 12703000000 |
| Saturday, January 1, 2022 | 752700000 | 13677000000 |
| Sunday, January 1, 2023 | 887600000 | 14771000000 |
| Monday, January 1, 2024 | 1007200000 | 14730000000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Pfizer Inc. and Neurocrine Biosciences, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, fluctuating around $14 billion annually. In contrast, Neurocrine Biosciences has seen a dramatic increase, with expenses growing from $18 million in 2014 to nearly $888 million in 2023, a staggering 4,800% rise.
This divergence highlights the different growth strategies of these companies. While Pfizer maintains a steady approach, Neurocrine's rapid expansion reflects its aggressive investment in growth and development. Understanding these trends provides valuable insights into how each company navigates the financial landscape, offering lessons in strategic cost management.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Neurocrine Biosciences, Inc.
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Pfizer Inc. vs GSK plc
Who Optimizes SG&A Costs Better? Pfizer Inc. or Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Pfizer Inc. vs Mesoblast Limited
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. and Summit Therapeutics Inc.: SG&A Spending Patterns Compared
Neurocrine Biosciences, Inc. vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Catalyst Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared